Optometry - Journal of the American Optometric Association
Volume 81, Issue 11 , Pages 580-586 , November 2010

Retinopathy associated with pegylated interferon and ribavirin treatment for chronic hepatitis C

  • Shelly Adams, O.D.

      Affiliations

    • Corresponding Author InformationCorresponding author: Shelly Adams, O.D., Veterans Affairs Southern Oregon Rehabilitation Center & Clinics, Optometry, 8495 Crater Lake Hwy, White City, Oregon 97503.
    • ,
  • Mark Ostermeier, O.D.

References 

  1. Panetta JD, Gilani N. Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2009;30:597–602
  2. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Int Med. 2006;144:705–714
  3. Kim ET, Kim LH, Lee JI, et al. Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin. Jpn J Ophthalmol. 2009;53:598–602
  4. Hepatitis C-global prevalence (update). Wkly Epidemiol Rec. 1999;74:425–427
  5. Chronic Hepatitis C: Current Disease Management. National Digestive Diseases Information Clearinghouse (NDDIC). Available at: http://digestive.niddk.nih.gov/ddiseases/pubs/chronichepc/index.htm. Last accessed January 1, 2010.
  6. Cuthbertson FM, Davies M, McKibbin M. Is screening for interferon retinopathy in hepatitis C justified?. Br J Opthalmol. 2004;88:1518–1520
  7. Sarasin-Filipowicz M. Interferon therapy of hepatitis C: molecular insights into success and failure. Swiss Medi Wkly. 2010;140(1-2):3–11
  8. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958–965
  9. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  10. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355
  11. Hasan F, Asker H, Al-Khaldi J, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol. 2004;99:1733–1737
  12. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–593
  13. Jain K, Lam WC, Waheeb S, et al. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol. 2001;85:1171–1173
  14. Lim JW, Shin MC. Pegylated-interferon-associated retinopathy in chronic hepatitis patients. Ophthalmoligica. 2010;224:224–229
  15. Patterson JL, Fernandez-Larson R. Molecular action of ribavirin. Rev Infect Dis. 1990;12:1332–1346
  16. Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fg 12 prothrombinase and preserves TH1 cytokine production but inhibits TH2 cytokine response. F Immunol. 1998;160:487–493
  17. Fried M. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36:S237–S244
  18. Tokai R, Ikeda T, Miyaura T, et al. Interferon-associated retinopathy and cystoid macular edema. Arch Ophthalmol. 2001;119:1077–1079
  19. Ikebe T, Nakatsuka K, Goto M, et al. A case of retinopathy induced by intravenous administration of interferon. Folia Ophthalmol Jpn. 1990;41:2291–2296
  20. Hayasaka S, Nagaki Y, Matsumoto M, et al. Interferon associated retinopathy. Br J Ophthalmol. 1998;82:323–325
  21. Hayasaka S, Fujii M, Yamamoto Y, et al. Retinopathy and subconjunctival hemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Opthalmol. 1995;79:150–152
  22. Hayasaka S, Okada M, Yamamoto S. Retinopathy in chronic hepatitis C patients treated by systemic interferon alfa-2b. F Rev Clin Ophthalmol (Ganka Rinsho Iho). 1996;1990:1274–1276
  23. Tu KL, Bowyer J, Schofield K, et al. Severe interferon associated retinopathy. Br J Opththalmol. 2003;87:247–248
  24. Wilson R. Visual side effects of pegylated interferon during therapy for chronic hepatitis C infection. J Clin Gastroenterol. 2004;38:717–722
  25. Ayaki M. Development of neovascular glaucoma in the course of interferon alfa therapy for hepatitis C. Br J Ophthalmol. 1994;78:238
  26. Purvin VA. Anterior ischemic optic neuropathy secondary to interferon. Arch Ophthalmol. 1995;113:1041–1044
  27. Wei YH, Wang IH, Woung LC, et al. Anterior ischemic optic neuropathy associated with pegylated interferon therapy for chronic hepatitis C. Ocul Immunol Inflamm. 2009;17:191–194
  28. Verdizer Y, Linhart Y, Loewenstein A, et al. Interferon-alpha-associated bilateral simultaneous ischemic optic neuropathy. J Neuroophthalmol. 2004;23:256–259
  29. Kuga K, Hasumura S, Nagamori S, et al. Intraocular hemorrhage developing during interferon therapy. Intern Med. 1996;35:15–18
  30. Kargi SH, Oz O, Ustundag Y, et al. Epiretinal membrane development during interferon treatment. Can J Opthalmol. 2003;38:610–612
  31. Lohmann CP, Kroher G, Bogenrieder T, et al. Severe loss of vision during adjuvant interferon alpha-2b treatment for malignant melanoma. Lancet. 1999;353:1326
  32. Suzuki T, Yonemura K, Miyaji T, et al. Progressive renal failure and blindness due to retinal hemorrhage after interferon therapy for hepatitis C virus-associated membranoproliferative glomerulonephritis. Intern Med. 2001;40:708–712
  33. Schulman J, Liang C, Kooragayala L, et al. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmology. 2003;110:437–442
  34. Nicolo M, Artoli S, LaMattina GC, et al. Branch retinal artery occlusion combined with branch retinal vein occlusion in a patient with hepatitis C treated with interferon and ribavirin. Eur J Opthalmol. 2005;15:811–814
  35. Kirati H, Irkec M. Presumed interferon-associated bilateral macular arterial branch obstruction. Eye. 2000;14:920–922
  36. Malik N, Sheth H, Ackerman N, et al. A prospective study of change in visual function in patients treated with pegylated interferon alpha of hepatitis C in the UK. Br J Opthalmol. 2008;92:256–258
  37. Zegans ME, Anninger W, Chapman C, et al. Ocular manifestations of hepatitis C virus infection. Curr Opin Opththalmol. 2002;13:423–427
  38. Soushi S, Kobayashi F, Obazawa H, et al. Evaluation of risk factors of interferon-associated retinopathy in patients with type C chronic active hepatitis. J Jpn Ophthalmol Soc (Nichigan-Kaishi). 1996;100:69–76
  39. Okuse C, Yotsuyanagi H, Nagase Y, et al. Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C. World J Gastroenterol. 2006;12(23):3756–3759
  40. Stoffeins BM. Interferon causes ischemic ocular diseases—case studies and review of the literature. Klin Monatsbl Augenheilkd. 2006;223:367–371
  41. Reynolds S, Rodman J. Hematological disorders and the retina. Rev Optom. 2009;145(suppl 1):3–4
  42. Carraro MC, Rossetti L, Gerli GC. Prevalence of retinopathy in patients with anemia or thrombocytopenia. Eur J Haematol. 2001;67:238–244
  43. Guyer DR, Teideman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol. 1993;111:350–356
  44. Nishiwaki H, Ogura Y, Miyamoto K, et al. Interferon alfa induces leukocyte capillary trapping in rat retinal microcirculation. Arch Opthalmol. 1996;114:726–730
  45. Nagaoka T, Sato E, Takahashi A, et al. Retinal circulatory changes associated with interferon-induced retinopathy in patients with hepatitis C. Invest Ophthalmol Vis Sci. 2007;48:368–375
  46. Takase B, Uehata A, Fujioka T, et al. Endothelial dysfunction and decreased exercise tolerance in interferon-alpha therapy in chronic hepatitis C: relation between exercise hyperemia and endothelial function. Clin Cardiol. 2001;24:286–290
  47. Nagaoka T, Yoshida A. Noninvasive evaluation of wall shear stress on retinal microcirculation in humans. Invest Ophthalmol Vis Sci. 2006;47:1113–1119
  48. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839–1850
  49. Kwo P, Lawitz E, McCone J, et al. HCV SPRINT-1 final results: SVR-24 from a phase 2 study of boceprevir plus pegintron (peginterferon alfa-2b)/ribavirin in treatment-naïve subjects with genotype-1 chronic hepatitis C. J Hepatol. 2009;50:S4

PII: S1529-1839(10)00315-5

doi: 10.1016/j.optm.2010.04.094

Optometry - Journal of the American Optometric Association
Volume 81, Issue 11 , Pages 580-586 , November 2010

Article Tools

* Image Usage & Resolution